Clinical Trial Update: RENACTIF: Reduction of the Thrombotic Phenotype in Renal Insufficiency With N-AcetylCysteine [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating N-acetylcysteine to reduce thrombotic phenotype in chronic kidney disease patients; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: Assistance Publique Hopitaux De Marseille | Conditions: Chronic Kidney Diseases | Phase 2 | Status: COMPLETED